ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

abelacimab

Also written as “Abelacimab”, “MAA868” and “MAA868 Cohort 1”.

In Novartis’s pipeline, FXI/FXIa inhibitor. Its studies are mostly in Atrial Fibrillation · Venous Thromboembolism, led by 2 companies.

Drug pageAbelacimab: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 22, 20218 company-led studies, 3 open or runningAcquisition: Novartis acquired Anthos Therapeutics, Apr 2025Next primary completion: Dec 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Anthos Therapeutics52 open or runningphase 3since Nov 22, 2021Dec 23, 2019Dec 30, 2027phase 3 · NCT05712200
Novartisits history only31 open or runningphase 3since Jul 28, 2026Jan 3, 2018Dec 30, 2030phase 3 · NCT07739888
  • Named in Novartis’s own pipeline as MAA868 (abelacimab), phase 3, as of Nov 16, 2026 (source).

Also a collaborator on its studies: Covance.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Anthos Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2018Named abelacimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, MAA868
  2. Dec 23, 2019First study: phase 2 study in Atrial FibrillationFirst studyNCT04213807 · 28 enrolled · United States
  3. Feb 11, 2021Phase 2 study in Atrial FibrillationNCT04755283 · 1,287 enrolled · United States, Canada, Czechia and more
  4. Nov 22, 20212 phase 3 studies in Venous ThromboembolismNCT05171075, NCT05171049
  5. Jan 12, 2023Phase 3 study in Atrial FibrillationNCT05712200 · 2,500 planned · United States, Argentina, Brazil and more
  6. Apr 2025Novartis acquired Anthos TherapeuticsAcquisitionWith it the rights Anthos held · completed · Blackstone Life Sciences and Anthos (release)

Ahead

  1. Dec 30, 2027Primary completion: phase 3 study in Atrial FibrillationNCT05712200

TargetBeta

“FXI/FXIa inhibitor”the company's pipeline, read by Claude · source
“Coagulation factor XI inhibitor”ChEMBL 37, by rule

Other programs on F11

ProgramCompanyFurthest phaseStudies
milvexianBristol-Myers Squibbphase 325
SHR-2004Jiangsu HengRui Medicinephase 35

Studies

All 5 Anthos Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05712200Atrial Fibrillation · United States, Argentina, Brazil and more3RecruitingDec 30, 20272,500
NCT05171075Venous Thromboembolism · United States, Australia, Austria and more3TerminatedApr 10, 2026417
NCT05171049Venous Thromboembolism · United States, Australia, Austria and more3TerminatedFeb 4, 20261,150
NCT04755283Atrial Fibrillation · United States, Canada, Czechia and more2Active, not recruitingFeb 15, 20241,287
NCT04213807Atrial Fibrillation · United States2CompletedDec 29, 202028

How it is read

Names in the registry

  • “Abelacimab”, 5 entries
  • “MAA868”, 2 entries
  • “MAA868 Cohort 1”, 1 entry
  • “MAA868 Cohort 2”, 1 entry
  • “MAA868 Cohort 3”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.